跳至主要内容

Compassionate Use of Midostaurin in Myeloid and Lymphoid Neoplasia with FGFR1 Abnormality

Read full paper at:
http://www.scirp.org/journal/PaperInformation.aspx?PaperID=50793#.VE8SF1fHRK0

Background: Patients with stem cell myeloproliferative disorders have a particularly poor prognosis and limited treatment options, i.e. mainly aggressive chemotherapy or allogeneic stem cell transplantation. In 2004, Chen et al. reported a patient presenting a t(8;13) (p11;q12) cytogenic anomaly who responded positively to treatment with PKC412 (midostaurin), an oral multi-targeted tyrosine kinase inhibitor. Here, we report a second case treated with the above-mentioned drug. Patient: A 71-year-old woman was diagnosed as having chronic myelogenous leukaemia with eosinophilia secondary to t(8;13) with FGFR1 involvement. Due to her age, an allogeneic stem cell transplantation was not possible. Treatment: A treatment combining aggressive chemotherapy and midostaurin was explored. The patient received one cycle of hyper-CVAD chemotherapy followed by maintenance therapy with midostaurin. A relapse occurred after six months, and she was treated with four more cycles of hyper-CVAD chemotherapy. The patient entered a complete clinical, haematological and cytogenetic remission. A maintenance therapy with midostaurin continued for four months until she developed a chemoresistant relapse followed by acute leukaemia. Conclusion: This is the second case of a t(8;13) myeloid and lymphoid neoplasm with FGFR1 abnormalities treated successfully with midostaurin. Midostaurin is administered orally, allows for outpatient care and in this case showed only occasional and minimal side effects. The combination of hyper-CVAD and midostaurin extended survival by 21 months without allogeneic transplantation. This case further supports the possibility of using midostaurin for the treatment of other diseases with FGFR1 dysregulations; however, specific clinical trials are needed to confirm this hypothesis.
Cite this paper
Beris, P. , Nagy, M. , Robert, D. , Samii, K. , McKee, T. and Schuler, J. (2014) Compassionate Use of Midostaurin in Myeloid and Lymphoid Neoplasia with FGFR1 Abnormality. Case Reports in Clinical Medicine, 3, 560-565. doi: 10.4236/crcm.2014.310122.

References


[1] Bain, B.J. (2010) Myeloid and Lymphoid Neoplasms with Eosinophilia and Abnormalities of PDGFRA, PDGFRB or FGFR1. Haematologica, 95, 696-698.
http://dx.doi.org/10.3324/haematol.2009.021675
[2] Valent, P., Horny, H.P., Bochner, B.S., Haferlach, T. and Reiter, A. (2012) Controversies and Open Questions in the Definitions and Classification of the Hypereosinophilic Syndromes and Eosinophilic Leukemias. Seminars in Hematology, 49, 171-181.
http://dx.doi.org/10.1053/j.seminhematol.2012.01.009
[3] Bain, B.J., Gilliland, D.G., Vardiman, J.W. and Horny, H.P. (2008) Chronic Eosinophilic Leukemia, Not Otherwise Specified. In: Swerdlow, S.H.C., Campo, E., Harris, N.L., et al., Eds., World Health Organization (WHO) Classification of Tumours, IARC Press, Lyon, 51-53.
[4] Bain, B.J., Gilliland, D.G., Vardiman, J.W. and Horny, H.P. (2008) Myeloid and Lymphoid Neoplasms with Eosinophilia and Abnormalities of PDGFRA, PDGFRB or FGFR1. In: Swerdlow, S.H.C., Campo, E., Harris, N.L., et al., Eds., World Health Organization (WHO) Classification of Tumours, IARC Press, Lyon, 51-53.
[5] Macdonald, D., Aguiar, R.C., Mason, P.J., Goldman, J.M. and Cross, N.C. (1995) A New Myeloproliferative Disorder Associated with Chromosomal Translocations Involving 8p11: A Review. Leukemia, 9, 1628-1630.
[6] Chen, J., Deangelo, D.J., Kutok, J.L., Williams, I.R., Lee, B.H., Wadleigh, M., Duclos, N., Cohen, S., Adelsperger, J., Okabe, R., Coburn, A., Galinsky, I., Huntly, B., Cohen, P.S., Meyer, T., Fabbro, D., Roesel, J., Banerji, L., Griffin, J.D., Xiao, S., Fletcher, J.A., Stone, R.M. and Gilliland, D.G. (2004) PKC412 Inhibits the Zinc Finger 198-Fibroblast Growth Factor Receptor 1 Fusion Tyrosine Kinase and Is Active in Treatment of Stem Cell Myeloproliferative Disorder. Proceedings of the National Academy of Sciences, 101, 14479-14484.
http://dx.doi.org/10.1073/pnas.0404438101
[7] Hatzimichael, E., Georgiou, G., Benetatos, L. and Briasoulis, E. (2013) Gene Mutations and Molecularly Targeted Therapies in Acute Myeloid Leukemia. American Journal of Blood Research, 3, 29-51.
[8] Savage, N., George, T.I. and Gotlib, J. (2013) Myeloid Neoplasms Associated with Eosinophilia and Rearrangement of PDGFRA, PDGFRB, and FGFR1: A Review. International Journal of Laboratory Hematology, 35, 491-500.
[9] Erba, H.P. (2010) Has There Been Progress in the Treatment of Older Patients with Acute Myeloid Leukemia? Best Practice Research Clinical Haematology, 23, 495-501.
http://dx.doi.org/10.1016/j.beha.2010.09.012
[10] Jackson, C.C., Medeiros, L.J. and Miranda, R.N. (2010) 8p11 Myeloproliferative Syndrome: A Review. Human Pathology, 41, 461-476.
http://dx.doi.org/10.1016/j.humpath.2009.11.003
[11] Valent, P., Gleich, G.J., Reiter, A., Roufosse, F., Weller, P.F., Hellmann, A., Metzgeroth, G., Leiferman, K.M., Arock, M., Sotlar, K., Butterfield, J.H., Cerny-Reiterer, S., Mayerhofer, M., Vandenberghe, P., Haferlach, T., Bochner, B.S., Gotlib, J., Horny, H.P., Simon, H.U. and Klion, A.D. (2012) Pathogenesis and Classification of Eosinophil Disorders: A Review of Recent Developments in the Field. Expert Review of Hematology, 5, 157-176.
http://dx.doi.org/10.1586/ehm.11.81
[12] Gotlib, J., Berube, C., Growney, J.D., Chen, C.C., George, T.I., Williams, C., Kajiguchi, T., Ruan, J., Lilleberg, S.L., Durocher, J.A., Lichy, J.H., Wang, Y., Cohen, P.S., Arber, D.A., Heinrich, M.C., Neckers, L., Galli, S.J., Gilliland, D.G. and Coutre, S.E. (2005) Activity of the Tyrosine Kinase Inhibitor PKC412 in a Patient with Mast Cell Leukemia with the D816V KIT Mutation. Blood, 106, 2865-2870.
http://dx.doi.org/10.1182/blood-2005-04-1568
[13] Fabbro, D., Ruetz, S., Bodis, S., Pruschy, M., Csermak, K., Man, A., Campochiaro, P., Wood, J., O’Reilly, T. and Meyer, T. (2000) PKC412—A Protein Kinase Inhibitor with a Broad Therapeutic Potential. Anti-Cancer Drug Design, 15, 17-28.
[14] Marte, B.M., Meyer, T., Stabel, S., Standke, G.J., Jaken, S., Fabbro, D. and Hynes, N.E. (1994) Protein Kinase C and Mammary Cell Differentiation: Involvement of Protein Kinase C Alpha in the Induction of Beta-Casein Expression. Cell Growth Differentiation, 5, 239-247.
[15] Growney, J.D., Clark, J.J., Adelsperger, J., Stone, R., Fabbro, D., Griffin, J.D. and Gilliland, D.G. (2005) Activation Mutations of Human c-KIT Resistant to Imatinib Mesylate Are Sensitive to the Tyrosine Kinase Inhibitor PKC412. Blood, 106, 721-724.
http://dx.doi.org/10.1182/blood-2004-12-4617
[16] Weisberg, E., Boulton, C., Kelly, L.M., Manley, P., Fabbro, D., Meyer, T., Gilliland, D.G. and Griffin, J.D. (2002) Inhibition of Mutant FLT3 Receptors in Leukemia Cells by the Small Molecule Tyrosine Kinase Inhibitor PKC412. Cancer Cell, 1, 433-443.
http://dx.doi.org/10.1016/S1535-6108(02)00069-7          eww141028lx
标签：

评论

发表评论

此博客中的热门博文

Does Immigration Promote the Investment of the Monopolistic Firm?

In the present paper, we examine the effect of increasing uncertainty of immigrants’ growth on the optimal timing of investment of a firm that has a monopolistic power over the labor market. It is revealed that when the uncertainty of immigrants’ growth is more than a threshold level, increasing uncertainty of immigrants’ growth accelerates the optimal timing of firms’ investment and enhances the economic growth, even if the uncertainty of immigrants’ growth is formulated by the geometric Brownian motion, which is in sharp contrast to the standard result that an increase in the uncertainty postpones the optimal timing. With an increase in the immigrants over the past ten years, workforces in the host countries have been growing significantly to the extent that the immigrants represent 70% of the increase in the workforce in Europe, and 47% in the United States as OECD indicates. In the present paper, we attempted to investigate the effect of increased uncertainty caused by the growi...
发表评论
阅读全文

Education Policy Implementation: A Mechanism for Enhancing Primary Education Development in Zanzibar

Education is one of the fundamental rights of individuals; therefore, the government of a country needs to develop and strengthen educational policy and quality as well as to ensure that everyone has equal access to basic education. The improvement of access and quality of education in the world is becoming as an essential factor in development, whereas the basic education (primary school), is acknowledged as a foundation of the higher educational development for every country. To fulfill this goal, governments introduce several policies and procedures; however, it requires some reforms and participation from the politician, policymakers, and other stakeholders to re-examine educational policy so that it can lead to multiplication and betterment of the reforms. Educational reforms actually focus on accountability. A positive educational development and reform is very challenging and needs more effort and strategy on how to use and utilize the resources effectively as such it can achie...
发表评论
阅读全文